The casualty has a weak radial pulse, a cold hand, and a wound that will not wait for the next convoy. Whole blood is not on this mission. A box of dried plasma is on the shelf. The question is what role it has when the preferred product cannot reach the casualty.
The Joint Trauma System added a dried-plasma guideline on 9 June 2026 and updated it on 19 August 2026 (JTS guideline: The Use of Dried Plasma in the Deployed Trauma System and Contingency Operations). The current 2026 TCCC guidance puts cold-stored low-titer O whole blood first for hemorrhagic shock; reconstituted dried plasma appears only when higher-priority products are unavailable (TCCC Guidelines, 1 May 2026).
Dried plasma is a bridge and a logistics tool. It does not replace whole blood or hemorrhage control.
The JTS guideline describes dried plasma as a contingency product for forward operations when whole blood or balanced component therapy is not readily available. It states that whole blood remains the preferred resuscitative fluid for severe hemorrhage and that dried plasma complements, rather than replaces, whole blood or balanced resuscitation (JTS dried-plasma guideline). That is the first decision point for a medic: identify the casualty who needs blood-based resuscitation, then select the best product that the approved command or theater protocol makes available.
The May 2026 TCCC hierarchy is practical under pressure. It lists cold-stored low-titer O whole blood, pre-screened low-titer O fresh whole blood, 1:1:1 plasma/RBC/platelet therapy, 1:1 plasma/RBC therapy, and then plasma or RBCs alone. Reconstituted dried plasma is grouped with plasma alone at the lower end of that sequence, and the guideline calls for reassessment after each unit (TCCC Guidelines, 1 May 2026). Dried plasma solves a supply problem. It does not change the priority of hemorrhage control or balanced resuscitation.
Frozen plasma depends on a cold chain and thawing. Dried plasma can be stored at room temperature and reconstituted at the point of care, which helps a forward system with limited refrigeration (Pusateri et al., 2025; FDA-DoD collaboration). Those are operational advantages, not clinical outcomes by themselves.
In August 2024, the FDA issued an Emergency Use Authorization for octaplasLG Powder, a lyophilized form of pooled plasma, for U.S. military forces treating emergent hemorrhage or coagulopathy during an emergency involving military combat agents when plasma is unavailable or impractical (FDA fact sheet for health care professionals). The authorization covers blood group A and AB products. The fact sheet says the product may be given to recipients of any blood group when the recipient’s group cannot be determined in an emergency, under the terms of the authorization (FDA fact sheet for health care professionals).
“Dried plasma” is a product class, not one universal vial. Know the product, authorization, diluent, administration set, contraindications, and medical direction before the mission. The JTS guideline’s August 2026 update adds clarification about IgA-deficiency contraindications (JTS dried-plasma guideline).
The current evidence supports a logistical and physiologic rationale. A 2025 military review describes freeze-dried plasma as rapidly available, easy to carry, and shelf-stable at room temperature (Pusateri et al., 2025). A 2025 laboratory study found largely comparable clot-formation properties and coagulation parameters to fresh-plasma controls, with some differences in fibrinolysis and the von Willebrand factor–ADAMTS13 axis (Shoara et al., 2025).
The human evidence calls for discipline. A 2024 observational study found insufficient evidence to conclude that freeze-dried plasma alone, blood products alone, or the combination produced different relative 24-hour mortality outcomes (Mould-Millman et al., 2024). A 2025 Canadian Armed Forces–linked review calls for pilot work, training, and outcome evaluation before broader adoption (Prifti et al., 2025). The honest operational claim is narrower: dried plasma can make plasma available where conventional plasma may not be. The evidence does not justify calling it a replacement for whole blood.
Teach dried plasma as a branching decision, not a product demonstration. Start with a casualty in hemorrhagic shock and three supply states: whole blood, component therapy, or only an authorized dried-plasma product. Make the learner name the hemorrhage-control action, product priority, and reassessment trigger before opening a package. The MilMedSim training route can hold that sequence.
Then add friction. The receiving team asks which product was used. The aircraft is delayed. The medic documents the unit, time, response, and next plan. The FY 2026 Joint En Route Care Guidelines emphasize reassessment during transport, secure interventions, and a clear verbal turnover. Those are exactly the behaviors a dried-plasma scenario should test.
The after-action review should ask four questions: Was the casualty a candidate for blood-based resuscitation? Was a higher-priority product available? Did the team follow the approved protocol? What changed after the unit was given? That turns the box into a readiness capability. The Global MedOps Command approach is useful here: train the consequence and decision, not only the package opening.
I have spent 25 years in emergency medicine, HEMS, and the Army National Guard watching logistics decide what medicine is possible. Whole blood is the right first answer for hemorrhagic shock when available under the governing protocol. Dried plasma earns its place because the forward system can fail to deliver that answer. A product that can sit forward without a freezer is a serious capability.
That being said, the box can create its own trap. People see a new capability and promote it above the casualty’s problem. Dried plasma does not stop the bleed. It does not replace whole blood. It does not remove the need to know the product label, the authorization, the contraindications, or the handoff. The honest answer is that the outcome evidence remains limited, and the right use will depend on the protocol and the mission. I want every medic to know what the powder can do and what it cannot do.
If you are the medic on the ground, practice the product decision before you need it. If you are a medical officer, audit whether the unit can name the priority order, the preparation steps, and the reassessment plan without opening a manual under fire. Dried plasma is a bridge. Treat it like one.
No. JTS calls it a complement and contingency option. TCCC places cold-stored low-titer O whole blood first and dried plasma lower when preferred products are unavailable (JTS dried-plasma guideline; TCCC Guidelines, 1 May 2026).
It can provide plasma without conventional frozen plasma’s refrigeration and thawing burden, making it useful forward when cold-chain support is limited (Pusateri et al., 2025; FDA fact sheet).
Current evidence does not establish a universal survival benefit. A 2024 observational study found insufficient evidence to conclude that freeze-dried plasma alone, blood products alone, or their combination produced different relative 24-hour mortality outcomes (Mould-Millman et al., 2024). Its clearest established advantage is the ability to make plasma available in austere settings where conventional plasma may not be practical.
If you're a combat medic, corpsman, flight medic, or any provider treating casualties in the field trying to understand how AI will actually impact your clinical practice — not just the hype — I put together a free practical guide. You can download it here: AI in EM Survival Guide.